




## MaaT Pharma Unveils the First GMP-Compliant European Fecal Microbiota Transfer Platform

**(Lyon, France – Novembre 7, 2016)** - Major treatments such as high-dose antibiotic therapies and chemotherapies can lead to serious complications and create a gut microbiota imbalance (*formerly called intestinal flora*). Thanks to the €16M funding round led by multiple venture capitalists, in the last 18 months, MaaT Pharma aims to correct this imbalance. This biotech company, a specialist in intestinal microbiota, has launched its clinical trials and officially opened its platform for the production of clinical batches on November 3<sup>rd</sup>, 2016.

### The world pioneer of fecal microbiota transfer to address unmet medical needs

Since the end of 2014, MaaT Pharma has worked with INRA to develop a multi-patented and **proprietary fecal microbiota transfer** to cure **dysbiosis (intestinal microbiota imbalance)**. The goal is to dramatically **lessen serious complications for weak patients or patients weakened after treatment**, including the multiple drug resistant (MDR) bacteria, one of today's global public health issues. This first European GMP-compliant platform has allowed MaaT Pharma to **produce clinical batches**, since July 2016. Several patients have already been administered.



### Lyon selected as the platform home, a quick and easy choice

*"The Lyon-Gerland area is a leading world district for health and biotechnology in Europe and it was an obvious choice for us to set-up our platform in this BioDistrict. I am not aware of any other equivalent places on a national level in France that could support biotech companies when they start as Lyon does. Everything is done to ease entrepreneurship thanks to the process for life sciences start-ups and to make sure we are on the right track using 'plug and play' programs. Our regional ecosystem is dynamic, global (including key players, universities, research facilities...), and easy to access,"* states Hervé Affagard, co-founder and CEO of MaaT Pharma.

### A technical and medical challenge

With its European platform, MaaT Pharma aims to **become the key partner** to treat dysbiosis. The new disruptive drug will be made available to university hospitals, Anti-Cancer Centers, and centers for the treatment of bone and joint infections. *"We are currently working with six centers in France: the Saint-Antoine hospital in Paris, the Hospices Civils de Lyon, the Nantes University Hospital, the Institut of Paoli-Calmettes in Marseille, the Institut Universitaire du Cancer in Toulouse and the Pitié-Salpêtrière Hospital in Paris. We have a national and global ambition and plan to increase our partners to world-renowned institutions. We have also initiated feasibility studies in Europe,"* underlines Hervé Affagard, co-founder and CEO of MaaT Pharma.

Next steps for the MaaT Pharma **international and multidisciplinary team** are to industrialize the process and to make this new class of **disruptive drug available to all weak patients or patients weakened after treatment**.



## An extraordinary entrepreneurial journey

After working as an Entrepreneur-in-Residence for Seventure Partners, Hervé Affagard partnered with Accinov in March 2015 to host the company that counted, at that time, only one person. Fast forward to today, and ten committed professionals have joined the team, several patents have been filed, and the first clinical trials have begun. Interest in **gut microbiota is very new** and there is a **real need to educate and create awareness among hospitals, employees, the general public, and investors**. MaaT Pharma plans to increase its headcount in the next 3 years, with 25 new employees who will soon come onboard.

## Next steps

"In record time, we succeeded in bringing together the necessary forces (including the French National Agency for Medicines and Health Products (ANSM), hospitals, and Contract Research Organizations) to start our first clinical trial with expected results by the end of the first half of 2017," states Corentin Le Camus, Director of Therapeutic Development at MaaT Pharma.

###

### About MaaT Pharma

Founded at the end of 2014 and based in Lyon (France), MaaT Pharma (Microbiota as a Therapy) is a microbiome-based pharmaceutical company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis (gut microbiota imbalances). MaaT Pharma is currently developing its first candidate using its proprietary Autologous Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. MaaT Pharma's revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.

For more information: <http://www.maatpharma.com>

Follow us on Twitter: [@MaaT\\_Pharma](https://twitter.com/MaaT_Pharma)

Follow us on LinkedIn: <http://www.linkedin.com/company/maat-pharma>

### Media Contact

Pauline Richaud, TBWA CORPORATE

Email: [pauline.richaud@tbwa-corporate.com](mailto:pauline.richaud@tbwa-corporate.com)

Ph.: +33 (0) 6 45 68 42 72